Fasenra OverviewBenralizumab (INN, trade name Fasenra) is a monoclonal antibody which developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125). Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016. It was approved by the US FDA in November 2017 for the treatment of severe eosinophilic asthma. References ^ Statement on an Nonproprietary Name adopted by the US...
Read more Fasenra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Benralizumab
Recent Fasenra Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 30mg/ml
NDC Database Records for Fasenra: (1 result)Sorted by National Drug Code
- 0310-1730 Fasenra 30 mg/ml Subcutaneous Injection, Solution by Astrazeneca Pharmaceuticals Lp